» Articles » PMID: 17167178

Promoter Methylation Precedes Chromosomal Alterations in Colorectal Cancer Development

Abstract

Background: Colorectal cancers are characterized by genetic and epigenetic alterations. This study aimed to explore the timing of promoter methylation and relationship with mutations and chromosomal alterations in colorectal carcinogenesis.

Methods: In a series of 47 nonprogressed adenomas, 41 progressed adenomas (malignant polyps), 38 colorectal carcinomas and 18 paired normal tissues, we evaluated promoter methylation status of hMLH1, O6MGMT, APC, p14ARF, p16INK4A, RASSF1A, GATA-4, GATA-5, and CHFR using methylation-specific PCR. Mutation status of TP53, APC and KRAS were studied by p53 immunohistochemistry and sequencing of the APC and KRAS mutation cluster regions. Chromosomal alterations were evaluated by comparative genomic hybridization.

Results: Our data demonstrate that nonprogressed adenomas, progressed adenomas and carcinomas show similar frequencies of promoter methylation for the majority of the genes. Normal tissues showed significantly lower frequencies of promoter methylation of APC, p16INK4A, GATA-4, and GATA-5 (P-values: 0.02, 0.02, 1.1x10(-5) and 0.008 respectively). P53 immunopositivity and chromosomal abnormalities occur predominantly in carcinomas (P values: 1.1x10(-5) and 4.1x10(-10)).

Conclusions: Since promoter methylation was already present in nonprogressed adenomas without chromosomal alterations, we conclude that promoter methylation can be regarded as an early event preceding TP53 mutation and chromosomal abnormalities in colorectal cancer development.

Citing Articles

Aberrant PRDM2 methylation as an early event in serrated lesions destined to evolve into microsatellite-instable colorectal cancers.

van Toledo D, Bleijenberg A, Venema A, de Wit M, van Eeden S, Meijer G J Pathol Clin Res. 2024; 10(2):e348.

PMID: 38380944 PMC: 10880511. DOI: 10.1002/cjp2.348.


Missed colorectal cancers in a fecal immunochemical test-based screening program: Molecular profiling of interval carcinomas.

van der Vlugt M, Carvalho B, Fliers J, Montazeri N, Rausch C, Grobbee E World J Gastrointest Oncol. 2022; 14(11):2195-2207.

PMID: 36438700 PMC: 9694267. DOI: 10.4251/wjgo.v14.i11.2195.


Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.

de Krijger M, Carvalho B, Rausch C, Bolijn A, Delis-van Diemen P, Tijssen M Inflamm Bowel Dis. 2022; 28(9):1309-1320.

PMID: 35554535 PMC: 9434447. DOI: 10.1093/ibd/izac087.


The Role of miRNAs, miRNA Clusters, and isomiRs in Development of Cancer Stem Cell Populations in Colorectal Cancer.

Stark V, Facey C, Viswanathan V, Boman B Int J Mol Sci. 2021; 22(3).

PMID: 33572600 PMC: 7867000. DOI: 10.3390/ijms22031424.


GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma.

Negroni C, Hilton D, Ercolano E, Adams C, Kurian K, Baiz D EBioMedicine. 2020; 59:102941.

PMID: 32810829 PMC: 7452696. DOI: 10.1016/j.ebiom.2020.102941.